Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

@article{Goyal2017PolyclonalSF,
  title={Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.},
  author={Lipika Goyal and Supriya Kumar Saha and Leah Y. Liu and Giulia Siravegna and Ignaty Leshchiner and Leanne G. Ahronian and Jochen K Lennerz and Phuong Nam Vu and Vikram Deshpande and Avinash R Kambadakone and Benedetta Mussolin and Stephanie M Reyes and Laura Noelle Henderson and Jiaoyuan Elisabeth Sun and Emily E Van Seventer and Joseph M Gurski and Sabrina Baltschukat and Barbara Schacher-Engstler and Louise Barys and Christelle Stamm and Pascal Furet and David P. Ryan and John Henry Stone and Anthony John Iafrate and Gad Getz and Diana Graus Porta and Ralph Tiedt and Alberto Bardelli and Dejan Juric and Ryan Bruce Corcoran and Nabeel Bardeesy and Andrew X. Zhu},
  journal={Cancer discovery},
  year={2017},
  volume={7 3},
  pages={252-263}
}
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but the durability of response was limited in some patients. Here, we report the molecular basis for acquired resistance to BGJ398 in three patients via integrative genomic characterization of cell-free… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

The epidemiology of cholangiocarcinoma

  • Y Shaib
  • Semin Liver Dis
  • 2004
Highly Influential
3 Excerpts

A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intol- erant to platinum-based chemotherapy

  • MM Javle, RT Shroff, AX Zhu, S Sadeghi, S Choo, MJ Borad
  • J Clin Oncol
  • 2015

Similar Papers

Loading similar papers…